Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

Vectibix® clinical studies for both first-line and monotherapy use in wild-type KRAS* mCRC1

The Prime Study

First-line study of Vectibix® + FOLFOX versus FOLFOX alone for progression-free survival (PFS)1,2

  • Phase 32
  • Open label1,2
  • Randomized1,2
  • Multicenter1,2
Learn More
The ASPECCT Study

Monotherapy, non-inferiority study of Q2W Vectibix® versus QW cetuximab for overall survival (OS)1,3

  • Phase 33
  • Open label1,3
  • Randomized1,3
  • Non-inferiority1,3
Learn more

*Exon 2 in codons 12 or 13. 1

mCRC = metastatic colorectal cancer; QW = weekly; Q2W = every two weeks.

PRIME = The Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy.

ASPECCT = A Study of Panitumumab Efficacy and Safety Compared to CeTuximab.

Site Map
×